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Manal Ebrahim11, Michael Bader2,3,4,5, Natalia Alenina3,4, Arnd Heuser3, Friedrich C. Luft1,3,4, 
Dominik N. Müller1,2,3,4,5, Ralf Dechend1,2,5,12,13* & Nadine Haase1,2,3,4,5,13
Type 2 diabetes mellitus and hypertension are two major risk factors leading to heart failure and 
cardiovascular damage. Lowering blood sugar by the sodium‑glucose co‑transporter 2 inhibitor 
empagliflozin provides cardiac protection. We established a new rat model that develops both 
inducible diabetes and genetic hypertension and investigated the effect of empagliflozin treatment 
to test the hypothesis if empagliflozin will be protective in a heart failure model which is not based 
on a primary vascular event. The transgenic Tet29 rat model for inducible diabetes was crossed 
with the mRen27 hypertensive rat to create a novel model for heart failure with two stressors. The 
diabetic, hypertensive heart failure rat (mRen27/tetO‑shIR) were treated with empagliflozin (10 mg/
kg/d) or vehicle for 4 weeks. Cardiovascular alterations were monitored by advanced speckle tracking 
echocardiography, gene expression analysis and immunohistological staining. The novel model 
with increased blood pressure und higher blood sugar levels had a reduced survival compared to 
controls. The rats develop heart failure with reduced ejection fraction. Empagliflozin lowered blood 
sugar levels compared to vehicle treated animals (182.3 ± 10.4 mg/dl vs. 359.4 ± 35.8 mg/dl) but not 
blood pressure (135.7 ± 10.3 mmHg vs. 128.2 ± 3.8 mmHg). The cardiac function was improved in 
all three global strains (global longitudinal strain − 8.5 ± 0.5% vs. − 5.5 ± 0.6%, global radial strain 
20.4 ± 2.7% vs. 8.8 ± 1.1%, global circumferential strain − 11.0 ± 0.7% vs. − 7.6 ± 0.8%) and by increased 
ejection fraction (42.8 ± 4.0% vs. 28.2 ± 3.0%). In addition, infiltration of macrophages was decreased 
by treatment (22.4 ± 1.7 vs. 32.3 ± 2.3 per field of view), despite mortality was not improved. 
Empagliflozin showed beneficial effects on cardiovascular dysfunction. In this novel rat model of 
combined hypertension and diabetes, the improvement in systolic and diastolic function was not 
secondary to a reduction in left ventricular mass or through modulation of the afterload, since blood 
pressure was not changed. The mRen27/tetO‑shIR strain should provide utility in separating blood 
sugar from blood pressure‑related treatment effects.
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Abbreviations
Anp  Atrial natriuretic peptide (gene)
Bnp  Brain natriuretic peptide (gene)
BNP  Brain natriuretic peptide (protein)
Col1  Collagen type 1
Ctgf  Connective tissue growth factor (gene)
DOX  Doxycycline
ED1  CD68+ macrophages
EF  Ejection fraction
empa  Empagliflozin
FN  Fibronectin
FS  Fractional shortening
GCS  Global circumferential strain
GLS  Global longitudinal strain
GRS  Global radial strain
HF  Heart failure
HFpEF  Heart failure with preserved ejection fraction
HFrEF  Heart failure with reduced ejection fraction
IVSd  Interventricular septum, diastole
LV  Left ventricular
LVPWd  Left ventricular posterior wall, diastole
MAP  Mean arterial blood pressure
mRen27  Hypertensive rat model
mRen27/tetO-shIR  Hypertensive, diabetic heart failure rat model
mRNA  Messenger ribonucleic acid
Myh6/7  Myosin heavy chain 6/7
RT-PCR  Real-time polymerase chain reaction
SD  Sprague Dawley
SEM  Standard error of the mean
SGLT2  Sodium-glucose co-transporter 2
SHR  Spontaneously hypertensive rats
Tet29  Diabetic rat model (tetO-shIR
Systolic blood pressure, smoking and glucose concentrations are the three main risk factors for cardiovascular disease 
in that  order1. Type 2 diabetes mellitus combined with hypertension is associated with an enhanced risk, demon-
strating the catastrophic combination of these two risk  factors2. Indeed, hypertension is present in over two-thirds 
of type 2 diabetes mellitus patients. Hypertension and type 2 diabetes mellitus together meld in heart failure. The 
prognosis is especially poor in type 2 diabetes mellitus patients because of cardiovascular end organ damage, leading 
to myocardial fibrosis and diastolic  dysfunction3. Patients suffering from type 2 diabetes mellitus exhibit subclinical 
cardiac dysfunction and renal impairment. However, some glucose-lowering therapies actually increase hospital 
 admissions4,5. It is known that lowering blood pressure has a dramatic effect on cardiovascular endpoints at all ages. 
In type 2 diabetes mellitus, the results are less  clear6. A new class of oral anti-diabetic drugs, sodium-glucose co-
transporter 2 (SGLT2) inhibitors, lowers blood glucose in an insulin-independent manner, by inhibiting renal glucose 
reabsorption in the proximal tubule. The recent Empagliflozin Cardiovascular Outcome Event Trial in type 2 diabetes 
(EMPA-REG OUTCOME) documented the impressive benefits obtained with empagliflozin (empa)7. Empa reduced 
the primary composite outcome of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3-point 
major adverse cardiovascular events), hospitalization for heart failure, and overall mortality compared with  placebo7. 
Myocardial infarction and stroke remained unchanged with therapy, suggesting effects not related to  thrombosis8. 
The fact that SGLT2 inhibitors reduce cardiovascular events by reducing primarily heart failure has  appeal9. New ESC 
guidelines on chronic coronary syndrome favor SGLT2 inhibitors as primary medication in untreated patients with 
diabetes before inducing  metformin10. However, metformin was the primary medication before applying empa in the 
clinical studies. The question now is whether empa is also cardio protective if administered as the only antidiabetic 
agent? Several other questions remained unanswered, such as the mechanism of action. An animal model of both 
hypertension and diabetes might have more utility than either condition alone. We generated a novel rodent model 
for heart failure by mating rats with type 2 diabetes and  hypertension11,12. Heart-failure is induced by two stressors, 
hypertension and diabetes, with state-of-the art  technology13,14.
The transgenic Tet29 rat model in which the insulin receptor is ubiquitously knocked down via doxycycline 
(dox)-induced RNA interference (small hairpin RNA), leading to insulin resistance and type 2 diabetes  mellitus11 
is crossed to the mRen27 rat. Transgenic rats carrying the murine Ren27 gene represent a monogenetic model of 
hypertension induced end organ damage characterized by low plasma renin and high extra renal expression of 
the  transgene12. It remains an unanswered question from the clinical trials whether the positive effects of SGLT2 
inhibitors on heart failure occur predominantly in heart failure with a preserved ejection fraction (HFpEF) or 
heart failure with a reduced ejection fraction (HFrEF).
Methods
Animal studies. All animal experiments were performed according to national and international guidelines 
and were approved by local authorities (State Office of Health and Social Affairs Berlin). We used 18 weeks old 
and body weight-matched male rats to characterize a new rat model for hypertensive and diabetic heart failure. 
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For this purpose, Sprague Dawley healthy control rats (SD; n = 5), diabetic rats (tetO-shIR; n = 10)11, hyperten-
sive rats (mRen27; n = 9)12, and crossbred diabetic and hypertensive rats (mRen27/tetO-shIR; n = 5) were moni-
tored for 9 weeks. All animals were bred at the Max-Delbrück Center for Molecular Medicine Berlin, Germany. 
Type 2 diabetes mellitus in the tetO-shIR and mRen27/tetO-shIR rats was induced by oral doxycycline (dox) 
application. TetO-shIR and mRen27/tetO-shIR rats received 2 mg/kg/d dox via drinking water until they were 
hyperglycemic with blood glucose level of between 300 and 400 mg/dL. Afterwards, 0.5 mg/kg/d dox was given 
to maintain the blood glucose level at that level over the entire period of 9 weeks. SD and mRen27 received 
water. After 8 weeks, blood pressure was monitored by tail cuff measurements and echocardiography was done. 
Blood glucose was measured manually with the Accu-Chek Aviva blood glucose meter (Roche, Germany) once 
a week. For the investigation of the effects of empa, 18 weeks old, age-matched and body weight-matched male 
mRen27/tetO-shIR rats were used. Type 2 diabetes mellitus was induced by dox as described above for 5 weeks. 
Afterwards, rats were randomly assigned to 2 experimental groups, vehicle-treated (water; n = 13) or treated 
with 10 mg/kg/d empa in the drinking water (n = 14). The treatment period was 4 weeks. At the end of the study 
rats were sacrificed by decapitation with prior anesthesia using isoflurane or due to predefined stopping criteria 
according with the European law for animal protection. Serum brain natriuretic peptide (BNP) was quantified 
according to the assay manual provided by the manufacturer (Abcam). The experimental unit is described by 
one single animal.
Echocardiography. As previously  described15, transthoracic echocardiography was performed under anes-
thesia (induction in a chamber with 2%, continuation with 1–1.5% isoflurane) on a tiltable, heated platform 
to maintain 37 °C body temperature, executed by a single examiner blinded to the treatment groups (n = 6–10 
rats per group). Chest hair was gently removed using a clipping machine and depilatory cream. A VisualSon-
ics VEVO 2,100 imaging system with a 21 MHz transducer (MS250) mounted on an integrated rail system was 
used, simultaneously recording an electrocardiogram. M-mode and B-mode images were obtained in paraster-
nal short and long axes views for measurement of diastolic left ventricular (LV) wall thickness (IVSd, LVPWd) 
and LV systolic function (EF, FS), respectively. Images were acquired and stored for offline analysis. Offline 
myocardial strain imaging analysis was performed by an investigator unaware of treatments using VisualSonics 
Vevo Strain software version 2.2.0 (Toronto, Canada) with a speckle tracking algorithm. B-Mode cine loops were 
checked for image quality with regard to differentiation of wall borders and absence of artefacts. Strain analysis 
was performed on three consecutive cardiac cycles. The endocardium of the LV was traced manually in paraster-
nal short- and long-axis view in end-diastole. The epicardium was automatically traced by the software, checked 
and manually adjusted if necessary for maximum tracking accuracy. Global strain values were obtained from the 
average of the six segments of the LV. Since echocardiography was performed under anesthesia due to animal 
welfare aspects and could therefore represent a limitation of this study, special attention was paid to a uniform 
procedure in the execution and evaluation of the data.
mRNA isolation and real‑time RT‑PCR. Total mRNA was isolated from the left ventricle of the heart 
(n = 5 per group) using QIAzol lysis reagent and Qiagen RNeasy mini kit (Qiagen) with on-column deoxyri-
bonuclease I step (Qiagen) according to manufacturer’s protocol as previously  described16. 2 μg of mRNA was 
reverse transcribed into cDNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
Real-time polymerase chain reaction (RT-PCR) was detected on ABI 7500 Fast Sequence Detection System 
(Applied Biosystems) and analyzed by 7500 Fast System Software (Applied Biosystems). Primers and probes 
(Supplementary table 1) were designed with PrimerExpress 3.0 (Applied Biosystems) and synthesized by Biotez 
(Germany). Analysis of target mRNA expression was performed with RT-PCR using the relative standard curve 
method. The expression level of the target genes was normalized by the expression of the 18S housekeeping gene. 
Samples were run in triplicates and mean was used for further calculations. The arbitrary units reflect the ratio of 
the target mRNA concentration divided by the concentration of 18S of the same sample.
Blood pressure and blood glucose measurement. Blood pressure measurement was performed by 
non-invasive tail cuff (CODA High Throughput System, Kent Scientific Corp., Torrington, USA). Blood glucose 
was measured by taking capillary blood droplets from tail puncture (Accu-Chek Aviva blood glucose meter, 
Roche, Mannheim, DEU). The measurements are carried out by animal keepers with decades of experience in a 
quiet environment to keep the stress for the animals as low as possible.
Immunohistochemistry. Paraffin-embedded hearts (vehicle n = 6, empa n = 8) were cut 4–6  μm thick 
and stained. Immunohistological techniques were performed as previously  described17. Heart sections were 
incubated with primary antibodies against rat macrophages (ED1; #MCA341R, Bio-Rad), fibronectin (FN; 
#ab23751, abcam), and collagen I (Col I; #131001, SouthernBiotech). Vectashield mounting medium with DAPI 
(#H-1200, Vector Laboratories) was used to stain nuclei. Semi-quantitative analyses of immunohistochemistry 
and histology were conducted without knowledge of the specific treatment and performed using Pannoramic 
MIDI II slide scanner (3D Histech, Hungary), CaseViewer and Image J software. For the histological and cardio-
myocyte analysis, 5 hearts of each group were examined. Picking out cardiac areas for immunohistology were 
standardized and uniformly distributed over the entire cross-section. Ten to fifteen different areas of each heart 
were analyzed. For the determination of the perivascular fibrosis, all vessels in the left ventricle were evaluated.
Statistics. Normal distribution was assessed by Kolmogorov–Smirnov test. Group differences were analyzed 
by two-tailed unpaired t-test, Mann–Whitney U test, one-way ANOVA with Tukey post hoc test or two-way 
ANOVA with Bonferroni post hoc test, as appropriate. Survival was examined using a Kaplan–Meier analysis. 
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The ROUT method was performed for outlier identification with an average false discovery rate less than 1%. 
A value of p < 0.05 was considered statistically significant. All data are presented as means ± SEM. Numbers of 
evaluated animals are given in the method description.
Ethics approval. Local authorities approved the studies (State Office of Health and Social Affairs Berlin, 
Germany), predefined stopping criteria according with the European law for animal protection were included.
Results
Hypertension and diabetes share many features and often occur together. We therefore bred a hypertensive 
rat model, the mRen27 rat, with an inducible type 2 diabetes mellitus rat model to generate the mRen27/tetO-
shIR rat (Fig. 1A). Hypertensive mRen27 rats and induced diabetic tetO-shIR rats exhibited no mortality in 
the investigated period. However, 9 weeks of combined hypertension and type 2 diabetes mellitus in mRen27/
Figure 1.  Characteristic of the new animal model. (A) Rat model for hypertensive and diabetic heart failure by 
breeding a hypertensive rat (mRen27), with an inducible diabetic rat (tetO-shIR) resulting in the hypertensive 
diabetic rat (mRen27/tetO-shIR). (B) Kaplan–Meier survival analysis of SD, diabetic (tetO-shIR), hypertensive 
(mRen27) and hypertensive diabetic rats (mRen27/tetO-shIR). At week 9, only 30% of hypertensive diabetic 
rats (mRen27/tetO-shIR) survived. Survival curves are statistically different by the log-rank test (p < 0.0001). 
No SD, diabetic (tetO-shIR) and hypertensive (mRen27) rats died before end of study. (C) Tail-cuff mean 
arterial pressure (MAP) was increased in mRen27 rats compared to SD, tetO-shIR and mRen27/tetO-shIR rats. 
The hypertensive diabetic rats (mRen27/tetO-shIR) showed significantly elevated MAP compared to SD and 
tetO-shIR rats. SD and tetO-shIR rats were normotensive. (D) Blood glucose level were significantly higher in 
tetO-shIR and mRen27/tetO-shIR rats compared to SD and mRen27 rats. 1-way ANOVA, *p < 0.05, ***p < 0.001, 
****p < 0.0001; data expressed as mean ± SEM.
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tetO-shIR rats reduced survival by 30% (Fig. 1B). The mRen27 rats had high mean arterial blood pressure 
(178 ± 10 mmHg), whereas the diabetic rats (90 ± 4 mmHg) and SD rats (90 ± 7 mmHg) were normotensive. The 
hypertensive diabetic rats (126 ± 5 mmHg) had lower blood pressures compared to the hypertensive mRen27 
rat; however, the values were still significantly higher compared to the normotensive SD rats (Fig. 1C). After 
induction by doxycycline, type 2 diabetes mellitus (370.0 ± 21.4 mg/dl) and hypertensive, type 2 diabetes mellitus 
rats (367.6 ± 20.1 mg/dl) exhibited higher blood glucose levels, whereas blood glucose levels in the hypertensive 
(110.3 ± 4.7 mg/dl) and SD controls (108.5 ± 3.3 mg/dl) were within normal limits (Fig. 1D).
The tetO-shIR rats also had hyperinsulinemia and increased C-peptide levels (data not shown). Echocar-
diographic assessment of the different models revealed a higher wall thickness (Fig. 2A) calculated by thickness 
of septum (IVSd) and posterior wall of the LV (LVPWd) in hypertensive mRen27 rats (4.6 ± 0.2 mm) while SD 
(3.5 ± 0.1 mm), diabetic (2.3 ± 0.1 mm), and hypertensive diabetic rats (3.0 ± 0.2 mm) had no thickened cardiac 
walls (Fig. 2A). The ejection fraction (Fig. 2B) and fractional shortening (Fig. 2C) values were slightly, but sig-
nificantly reduced in both diabetic (EF 42.8 ± 4.0%, FS 21.8 ± 1.4%) and hypersensitive rats (EF 39.2 ± 2.7%, FS 
15.4 ± 1.8%) compared to SD rats (EF 60.1 ± 2.1%, FS 31.9 ± 1.4%). Systolic heart function was further diminished 
in the hypertensive type 2 diabetes mellitus rats (EF 28.2 ± 3.0%, FS 15.0 ± 2.1%).
Two-dimensional speckle tracking echocardiography-derived measurement of LV strain and strain rate was 
performed to examine LV myocardial performance. Global longitudinal strain (GLS, Fig. 2D), global radial strain 
(GRS, Fig. 2E), and global circumferential strain (GCS, Fig. 2F) were significantly decreased in diabetic (GLS 
− 10.4 ± 1.0%, GRS 15.2 ± 1.4%, GCS − 16.3 ± 1.2%), hypersensitive (GLS − 11.2 ± 0.8%, GRS 19.3 ± 2.1%, GCS 
− 9.7 ± 1.1%) and hypertensive diabetic rats (GLS − 5.5 ± 0.6%, GRS 8.8 ± 1.1%, GCS − 7.6 ± 0.8%) compared with 
SD rats (GLS − 19.1 ± 0.7%, GRS 28.5 ± 3.2%, GCS − 19.3 ± 0.5%). Similar results were observed for the respective 
global strain rates (data not shown).
According our empa study design (Fig. 3A), we investigated the effects of empa on the cardiac target-organ 
damage in the hypertensive diabetic rats (mRen27/tetO-shIR). The survival rates (Fig. 3B) during the 4 weeks 
of treatment were unchanged between the empa (70.0%) and vehicle group (68.4%). Treatment of the hyper-
tensive diabetic rats by empa had no effect on the blood pressure (Fig. 3C). Empa treatment led to significant 
lower blood glucose level (Fig. 3D). Glucose level decreased from 359.4 ± 35.8 mg/dl in vehicle treated rats to 
182.3 ± 10.4 mg/dl in empa treated ones. The drinking volumes of empa treated rats were unaltered compared 
to the vehicle group (Fig. 3E).
We then assessed the effect of empa on cardiac function by echocardiography. No effects of empa treatment 
on wall thickness could be detected (Fig. 4A). Empa significantly increased the ejection fraction (42.8 ± 4.0%) and 
fractional shortening (22.6 ± 2.9%) compared to vehicle treated hypertensive diabetic rats (Fig. 4B-C). Moreover, 
empa has a positive effect on all 3 global strains. Global longitudinal (− 8.5 ± 0.5%), radial (20.4 ± 2.7%) and cir-
cumferential (− 11.0 ± 0.7%) strains were significantly enhanced by empa treatment compared to the vehicle group 
(Fig. 4D-F). Similar results were observed for the global longitudinal and radial strain rates (data not shown).
Figure 2.  Functional analysis by Speckle Tracking Echocardiography. (A) Hypertensive rats (mRen27) showed 
an increased wall thickness (IVSd + LVPWd) compared to SD, tetO-shIR and mRen27/tetO-shIR rats. Diabetic 
(tetO-shIR) and hypertensive diabetic rats (mRen27/tetO-shIR) had no thickened cardiac walls. (B) Ejection 
fraction and (C) fractional shortening were significantly reduced in tetO-shIR, mRen27 and mRen27/tetO-
shIR rats compared to SD. (D) Global longitudinal strain was significantly reduced in tetO-shIR, mRen27 and 
mRen27/tetO-shIR rats compared to SD, as were (E) global radial strain and (F) global circumferential strain. 
1-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; data expressed as mean ± SEM.
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The mRNA expression level of the cardiac marker Anp (1.37 ± 0.45 vs. 1.17 ± 0.20), Bnp (1.10 ± 0.05 vs. 
1.26 ± 0.12), Fn (1.57 ± 0.31 vs. 0.93 ± 0.19) and Ctgf (0.99 ± 0.12 vs. 0.82 ± 0.08) were unchanged. Only an increase 
in the ratio of Myh6/Mhy7 mRNA expression in empa treated rats (0.14 ± 0.05) compared to vehicle treated 
animals (0.40 ± 0.09) were detectable (Fig. 4G). Additionally, we analyzed circulating BNP levels that were also 
unaltered by empa treatment (data not shown). Immunohistochemical staining for cardiac macrophage infil-
tration (ED1), interstitial (fibronectin) and perivascular fibrosis (collagen I) was also investigated. Macrophage 
infiltration (Fig. 5A) was decreased in the cardiac tissue in the empa treated rats (22.4 ± 1.7 per fov) compared 
to vehicle treated (32.3 ± 2.3 per fov) whereas interstitial (Fig. 5B) and perivascular (Fig. 5C) fibrosis was not 
affected by empa treatment.
Figure 3.  Study design and outcome after empa treatment. (A) Experimental flow chart of EMPA study design. 
(B) Kaplan–Meier survival analysis showed no effect of empa treatment on survival and no effect on (C) mean 
arterial blood pressure. (D) Blood glucose level were significantly reduced by empa during the treatment 
period. (E) Empa treatment had no effect on the drinking volume. 2-way ANOVA, **p < 0.01, ***p < 0.001; data 
expressed as mean ± SEM.
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Discussion
We investigated the combined effects of hypertension and hyperglycemia on end-organ damage, focusing on the 
heart. We used a well-established transgenic rat model, overexpressing the mouse salivary-gland renin gene. This 
model is based on increased angiotensin II production resulting in a rightward shift in the pressure natriuresis 
 curve18. We crossed these animals with a unique tetracycline-inducible type 2 diabetes mellitus technique where 
insulin resistance results from downregulation of the insulin  receptor11. Almost two third of the hypertensive 
type 2 diabetes mellitus rats died between week 6 and 9 in our experiment, underscoring the lethality of hyperten-
sion plus hyperglycemia-induced heart failure. Surviving rats that could be measured had a marked reduction of 
systolic function and the worst global longitudinal strain, radial strain, and circumferential strain, thus we have 
introduced a novel model of two step heart failure (HF). In most rodent HF models, HF develops gradually over 
time due to a single stimulus. However, in human HF multiple factors are involved and trigger decompensation 
episodes. Among these factors, arterial hypertension is a prevalent trigger for decompensation episodes. We 
succeeded in establishing a novel HF rat model, which combines two incumbent protocols to achieve both the 
development of HF and the possibility to add a second stimulus to induce (HFrEF).
Figure 4.  Speckle Trackle Echocardiography and gene expression analysis after empa treatment. (A) No effects 
of empa treatment on wall thickness could be detected. (B) Ejection fraction and (C) fractional shortening were 
significantly increased by empa. (D) Global longitudinal strain was significantly elevated by empa treatment, as 
were (E) global radial strain and (F) global circumferential. (G) Heatmap of gene expression values in relation 
to 18S housekeeper are shown for every single animal. Relative gene expression is illustrated in corresponding 
color. Statistical outliers are marked with X. There is no change in cardiac atrial natriuretic peptide (Anp), brain 
natriuretic peptide (Bnp), fibronectin (Fn) or connective tissue growth factor (Ctgf) mRNA expression due to 
empa treatment. The ratio of alpha (Mhy6) and beta myosin heavy chain (Mhy7) mRNA expression is increased 
by treatment. Students t-test, *p < 0.05 **p < 0.01; data expressed as mean ± SEM.
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Hypertensive diabetic rats as a model have been investigated earlier. Iams and Wexler produced diabetes with 
alloxan in spontaneously hypertensive rats (SHR) in  197719. Mortality was high and animals became cachectic 
and moribund, probably related to acute metabolic disturbances rather than target-organ damage. The authors 
did not report data regarding blood pressure. Streptozotocin has also been commonly given to SHR. Hori et al.20 
reported on basement membrane changes in various tissue but also did not report on blood pressure-related 
effects. Techniques designed to destroy islet beta cells are more akin to type 1 diabetes mellitus rather than 
type 2 diabetes mellitus. Rats with type 2 diabetes mellitus present a significant challenge. Most rodent models 
are genetically or chemically modified to produce diabetes. Commonly high-fat-feeding is required, the length 
of time to develop diabetes is quite long and the phenotype is variable. The Nile rat may be an  exception21. Nile 
rats develop diabetes within 8–10 weeks with high-carbohydrate diet similar to humans, and are protected by 
high-fat, low-glycemic load  intake21. That model, with less carefully defined insulin levels, proved unpractical 
for our purposes. Thus, we selected the tetO-shIR rat, which allowed us to avoid additional dietary manipula-
tions. Another unique advantage is that the type 2 diabetes mellitus can be turned on and off with tetracycline.
We tested the hypothesis if empagliflozin will be protective in a heart failure model which is not based on a 
primary vascular event. Controls were mRen27/tetO-shIR given vehicle. Empa lowered plasma glucose levels 
from 400 mg/dL to under 200 mg/dL, a remarkable reduction based on increased glucose excretion alone. Blood 
pressure was not changed by this treatment. Nonetheless, empa improved cardiac function by increasing ejection 
fraction and fractional shortening compared to vehicle-treated controls. Moreover, empa has a positive effect on 
all 3 global strains. Global longitudinal, radial, and circumferential strains were significantly enhanced by empa 
treatment compared to the vehicle group. Since no cardiac expression of SGLT2 receptors has been described, 
it is difficult to postulate any direct effect of the drug on the myocardium per se. However, it is possible that 
empagliflozin binds to myocardial receptors or substrates other than SGLT2. In our model the improvement in 
systolic and diastolic function was not secondary to a reduction in left ventricular mass or through modification 
of the afterload since blood pressure was not changed.
Empa has been previously studied in other rodent models of hypertension and diabetes. Younis et al. studied 
the Cohen Rosenthal diabetic hypertensive  rat22. This model is an SHR cross with the Cohen diabetic rat. Unlike 
Figure 5.  Protein expression after empa treatment. (A) Representative image of ED-1 IHC staining for 
macrophages in the heart from empa and vehicle-treated rats. The number of macrophages was decreased in the 
heart of empa treated rats. (B) Representative image of fibronectin IHC staining in the hearts from empa and 
vehicle-treated rats. Interstitial cardiac fibrosis was estimated as fibronectin-positive area per view field. Heart 
sections of empa and vehicle-treated rats showed no differences in cardiac interstitial fibrosis. (C) Representative 
image of collagen I IHC staining in the hearts from empa and vehicle-treated rats. Perivascular fibrosis area 
was normalized to vessel media cross-sectional area. Heart sections of empa and vehicle-treated rats showed no 
differences in cardiac perivascular fibrosis. Students t-test, *** p < 0.001; data expressed as mean ± SEM.
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in our model empa lowered blood pressure by 15 mmHg and also reduced left ventricular mass and systolic dila-
tation. Steven et al. also reported favorable results in the Zucker diabetic fatty  rat23. They found that endothelial 
function was improved and inflammatory markers were reduced. Similarly, Zhou and Wu observed that empa 
treatment in streptozotocin-induced diabetes reduced serum glucose, while improving cardiac function and 
lowering expression of glucose-regulated protein-78 and enhancer-binding protein homologous  protein24. Thus, 
it is obvious that several, putative mechanisms underlying SGLT2 inhibitor-associated cardiovascular benefits 
occur as in patients as in rodents.
Whether or not the mechanism(s) involved in glycemic control and cardiovascular risk reduction are dis-
sociated and/or follow a different dose–response-curve is unclear. Due to the profound and early effects of 
empa on HF in patients and the fact that they were not due to improvement in atherothrombotic complications 
(myocardial infarction and stroke remained unchanged), it is difficult to ascribe all these salubrious effects solely 
to serum glucose  reduction25.
Ascribing the favorable effects to altered ventricular loading conditions secondary to a reduction in preload 
primarily due to the diuretic and natriuretic effects is an alternative mechanism. SGLT2 inhibition in the proxi-
mal tubule leads to natriuresis and glucosuria, and the ensuing osmotic diuresis may be favorable, particularly 
in the diabetic and hypertensive heart, which functions on a steep Frank-Starling curve. We observed no effects 
of empa on drinking volume, although we could not monitor daily urinary output. This must be kept in mind 
when comparing the circulating volumes. In patients with heart failure, a differential effect in the regulation 
of interstitial fluid (versus intravascular volume) may be particularly important, in many of whom there is 
intravascular contraction, often exacerbated by diuresis. The ability to selectively reduce interstitial fluid may 
be a unique feature of SGLT2 inhibitors. Other diuretic SGLT2 inhibitors may directly inhibit the Na+/H+ 
exchanger 1 isoform in the  myocardium26,27, reduced cytoplasmic sodium and calcium levels, while increasing 
mitochondrial calcium levels.
SGLT2 inhibitors have shown to optimize cardiac energy metabolism and subsequently improve myocardial 
energetics and substrate efficiency. In a recent study empagliflozin increased ketone consumption, reduced 
cardiac lactate production and glucose consumption after myocardial infarction in  pigs28. Alternatively empa 
inhibits the Na+/H+ exchanger, lowering cytosolic sodium and calcium levels and increasing mitochondrial 
calcium  concentrations27.
Taken together, our observations suggest the potential of empagliflozin to favorably promote left ventricular 
reverse remodeling and improve diastolic function in patients with type 2 diabetes and hypertension induced 
cardiovascular disease. A trial to test the effects of empa on the heart in patients is  underway29. There is a rea-
son to be optimistic since only SGLT2 inhibitors and glucagon-like peptide 1 agonists have been shown to any 
favorable effects on reducing mortality in type 2 diabetes mellitus  patients30.
Conclusion
The EMPA-REG OUTCOME trial documented impressive empagliflozin benefits on heart failure in diabetic 
patients with cardiovascular disease. A cardiovascular protective effect was more primary on preventing systolic 
heart failure morbidity and mortality than on preventing vascular events such as stroke and acute myocardial 
infarction. New ESC guidelines on chronic coronary syndromes favor SGLT2 inhibitors as primary medica-
tion in untreated patients with diabetes before introducing metformin. The key question of this study was if 
empagliflozin will be protective in a heart failure model which is not induced by a primary vascular event, such 
as myocardial infarction, leading to heart failure with reduced ejection fraction. Therefore, we developed an 
innovative rodent model for HFpEF which progresses to heart failure with mildly reduced ejection fraction. 
Empagliflozin ameliorated cardiovascular dysfunction in this model. The beneficial effect was not secondary to 
a reduction in LV mass or through modulation of the blood pressure. In future, SGLT2 inhibitors will become 
an important primary vascular preventive pillar next to lipid lowering and platelet inhibition independent of the 
diagnosis diabetes. Future studies will determine the exact mode of action and the patient groups with chronic 
coronary syndrome and heart failure who will benefit most.
Data availability
The datasets used and analysed during the current study are available from the corresponding author on reason-
able request.
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